Telix acquires assets targeting FAP in nuclear medicine
AuntMinnie
NOVEMBER 20, 2024
Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine. Telix said these new therapeutic assets are differentiated by a structure that drives extended tumor retention while minimizing off-target uptake.
Let's personalize your content